An intracellular antibody can suppress tumorigenicity in Hepatitis B virus X-expressing cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 5, p. 569, doi. 10.1007/s00262-005-0037-2
- Publication type:
- Article
Works matching IS 03407004 AND DT 2006 AND VI 55 AND IP 5
Results: 13
1
2
Tumor stroma-associated antigens for anti-cancer immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 5, p. 481, doi. 10.1007/s00262-005-0070-1
- Publication type:
- Article
3
Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 5, p. 588, doi. 10.1007/s00262-005-0051-4
- Publication type:
- Article
4
Lung squamous cell carcinoma and adenocarcinoma cell lines usedifferent mediators to induce comparable phenotypic and functionalchanges in human monocyte-derived dendritic cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 5, p. 598, doi. 10.1007/s00262-005-0060-3
- Publication type:
- Article
5
CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 5, p. 515, doi. 10.1007/s00262-005-0009-6
- Publication type:
- Article
6
Spontaneous elicitation of potent antitumor immunity and eradication of established tumors by administration of DNA encoding soluble transforming growth factor-b II receptor without active antigen-sensitization.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 5, p. 579, doi. 10.1007/s00262-005-0044-3
- Publication type:
- Article
7
Tumor skewing of CD34+ cell differentiation from a dendritic cell pathway into endothelial cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 5, p. 558, doi. 10.1007/s00262-005-0036-3
- Publication type:
- Article
8
Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 5, p. 495, doi. 10.1007/s00262-005-0023-8
- By:
- Publication type:
- Article
9
Anti-tumor activity of dendritic cells transfected with mRNA for receptor for hyaluronan-mediated motility is mediated by CD4<sup>+</sup> T cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 5, p. 538, doi. 10.1007/s00262-005-0027-4
- By:
- Publication type:
- Article
10
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 5, p. 503, doi. 10.1007/s00262-005-0001-1
- By:
- Publication type:
- Article
11
Serum antibodies to EpCAM in healthy donors but not ulcerative colitis patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 5, p. 528, doi. 10.1007/s00262-005-0026-5
- By:
- Publication type:
- Article
12
Gene transfer preferentially selects MHC class I positive tumour cells and enhances tumour immunogenicity.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 5, p. 547, doi. 10.1007/s00262-005-0035-4
- By:
- Publication type:
- Article
13
Strategies for immune intervention.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 5, p. 612, doi. 10.1007/s00262-005-0113-7
- By:
- Publication type:
- Article